Field guide // dosing context
KLOW peptide dosage: what the research vial holds, and why there is no human number
The canonical 80 mg composition, the half-life mismatch among the four arms, and why four component doses do not add into one KLOW dose.
The short version
There is no validated human KLOW peptide dosage, and this page does not invent one. What exists is research-handling context. The canonical research vial holds 80 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. Those four numbers describe what is in the vial — not how much a person should use. Two things stop them from adding up to a single "KLOW dose." First, the four peptides were studied separately, at different doses, in different species and by different routes, so there is no shared scale to add on. Second, they clear the body at very different speeds: the small tripeptides KPV and GHK-Cu disappear fast, while BPC-157 lingers longer — so one shared dose cannot keep all four present at the same time. We report the research numbers and the chemistry. We do not report a human protocol.
KLOW Dosing in the Research Context
In the research context, KLOW peptide dosage is described by the vial, not by a schedule. The most widely listed composition is 80 mg total — GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg — reconstituted with bacteriostatic water for laboratory handling [1]. Component-level research doses differ widely: thymosin beta-4 stimulated keratinocyte migration at as little as 10 pg in vitro [1]; BPC-157 was given to rats at 10 micrograms, 10 nanograms or 10 picograms per animal, once daily intraperitoneally [2]; KPV acted at 10 nM in cells and 100 microM in mouse drinking water [3]; GHK-Cu works at nanomolar concentrations in vitro and in topical formulations clinically [4]. None of these is additive into a single human figure, and none is a recommendation.
What is in the 80 mg vial
The canonical 80 mg vial is 62.5% GHK-Cu by mass (50 mg), with BPC-157, TB-500 and KPV each at 10 mg [1]. GHK-Cu's dominance is why the reconstituted solution can carry a faint blue tint — that is the copper(II) it chelates, not a dye. The peptides remain four separate molecules co-dissolved at fixed ratios; the blend is a mixture, not a defined substance, which is why no single CAS number, UNII or PubChem identifier exists for KLOW [1]. The per-component identifiers (KPV 342.44 Da, GHK-Cu 402.92 Da, BPC-157 1419.53 Da, TB-500 Ac-LKKTETQ 889.02 Da) live on the four-peptide blend overview and the references page.
The pharmacokinetic mismatch
The four arms have markedly different reported half-lives, and that mismatch is the heart of the dosing problem. The tripeptides KPV and GHK-Cu clear far faster than the larger BPC-157, and the TB-500 fragment behaves differently from native thymosin beta-4 [1]. Because of this, a single co-formulated dose cannot hold all four at matched exposures — by the time the slow arm is still working, the fast arms may be long gone. This is a structural fact of mixing four peptides with different clearance rates into one vial, and it is one reason "synergy" claims for the blend remain extrapolation rather than evidence.
Human clinical dosing data
There is none for the four-peptide blend [1]. Component human data are thin and do not transfer to a blend dose: GHK-Cu has topical cosmetic and wound data; BPC-157 has one 2025 IV safety pilot (10 mg on day 1, 20 mg on day 2, in two healthy adults, well tolerated) plus small case series [8]; thymosin beta-4 — not the TB-500 fragment — has early-phase trials; KPV human data are limited to delivery pilots [1]. We cite these as the state of the record, not as dosing instructions.